IgA Nephropathy
Conditions
Interventions
Treatment group:Basic treatment + potassium irbesartan 50mg qd + Huangqi Xiaobai granules
Control group:Basic treatment + potassium irbesartan 50mg qd + placebo
Sponsors
Yueyang Integrated Traditional Chinese and Western Medicine Hospital, Affiliated with Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Aged =18 and =75 years, gender not limited; 2.Pathologically diagnosed with IgA Nephropathy; 3.Kidney function: stages 1-2; 4.Traditional Chinese medicine syndrome differentiation meets the criteria of dampness, stasis, lung-spleen qi deficiency; 5.24-hour urine protein quantification =0.3g and =2.5g; 6.Participants who understand, agree to participate in the study, and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Received immunosuppressive or cytotoxic therapy for >4 weeks within the past 3 months; 2.Received a dosage of glucocorticoids (prednisone or prednisolone) >20mg/d for >4 weeks within the past 3 months; 3.Acute or rapidly progressive nephritis, acute progressive IgA Nephropathy; 4.Active hepatitis B with persistent abnormal liver function transaminases; 5.Patients with malignant tumors or a history of malignant tumors, HIV infection, psychiatric history, acute central nervous system disorders, severe gastrointestinal diseases, or contraindications to glucocorticoid use; 6.Abnormal glucose metabolism, fasting blood glucose >6.2mmol/L; 7.Pregnant or lactating women; 8.Participants currently enrolled in other clinical trials; 9.Complications that are life-threatening, such as severe infection or severe organ dysfunction; 10.Secondary factors causing IgA diseases, such as allergic purpura nephritis, chronic alcoholic liver disease, ankylosing spondylitis, psoriasis, lupus nephritis, etc.; severe primary diseases affecting the heart, brain, liver, and hematopoietic system; psychiatric patients; participants allergic to the investigational drug or intolerant to known adverse reactions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24-hour urine protein quantification;Traditional Chinese medicine syndrome; | — |
Secondary
| Measure | Time frame |
|---|---|
| Glomerular filtration rate;Serum creatinine;Complete Blood Count;Liver function;Pplasma potassium;Electrocardiogram; | — |
Countries
China
Contacts
Public ContactQian Jingfeng
Yueyang Integrated Traditional Chinese and Western Medicine Hospital, Affiliated with Shanghai University of Traditional Chinese Medicine
Outcome results
None listed